Last reviewed · How we verify
NCT04227678: AGL12
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
NA trial testing Heparin in Lipoprotein Lipase Deficiency in 16 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Université de Sherbrooke |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 16 |
| Start date | 9 December 2019 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 March 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Heparin (HEPARIN) — full drug profile →
- liquid meal
Conditions studied
- Lipoprotein Lipase Deficiency — all drugs for Lipoprotein Lipase Deficiency →
Sponsor
Université de Sherbrooke — full company profile →
Who can join
Adults 18 to 75, any sex, with Lipoprotein Lipase Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency (LPLD) display during their whole life very high plasma TG levels often associated with episodes of postprandial abdominal pain, malaise, blurred vision, dizziness (hyperchylomicronemia syndrome) that may lead to recurrent pancreatitis episodes. Because of their very slow clearance in blood of their chylomicron-TG, these patients need to severely restrict their dietary fat intake to avoid these complications. Fortunately, novel treatments are being developed to circumvent LPL deficiency (LPLD) metabolic effect on chylomicron-TG clearance. However, there is no data on how LPLD affect organ-specific dietary fatty acid metabolism nor how the novel therapeutic agents may change this metabolism. For example, it is currently not understood how subjects with LPLD store their DFA into adipose tissues and whether they are able to use DFA as a fuel to sustain their cardiac metabolism, as healthy individuals do. This study aims to better understand theses two questions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04227678
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Heparin
Trials testing the same drug.
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT06453876 — PERCUTANEOUS EMBOLECTOMY, ULTRASOUND ASSISTED LOW DOSE THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBO · Phase 3 · not yet recruiting
- NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
- NCT06549842 — Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial · NA · completed
- NCT05848713 — AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia · Phase 3 · recruiting
Other Université de Sherbrooke trials
Trials by the same sponsor.
- NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
- NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
- NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04227678 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04227678.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing